Clinical trial
Interferon Alfa in Treating Patients With Recurrent Unresectable Meningiomas and…
NCT00002965 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00002965 |
|---|---|
| Title | Interferon Alfa in Treating Patients With Recurrent Unresectable Meningiomas and Malignant Meningiomas |
| Official title | Phase II Study to Evaluate the Efficacy of Recombinant Interferon-Alpha in the Treatment of Recurrent Unresectable Meningiomas and Malignant Meningiomas |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Brain and Central Nervous System Tumors |
| Intervention type | Biological |
| Interventions | Recombinant Interferon Alfa (INF alpha) |
| Enrollment | 16 |
| Start date | Jan 1, 1997 |
| Primary completion | Mar 1, 2003 |
| Completion | Mar 1, 2003 |
| First posted | Jul 11, 2003 |
| Last update posted | Dec 22, 2023 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: